Asset
OMEGA-3-PENTAENOIC ACIDS
Matinas Biopharma Holdings Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04662528 | phase3 | withdrawn | 2021-06-01 | 2022-08-01 | Matinas Biopharma, Inc | Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL |
FDA applications (0)
This company has no applications containing this asset.